[go: up one dir, main page]

US20140178993A1 - Method and applications of peptide-mediated mitochondrial delivery system - Google Patents

Method and applications of peptide-mediated mitochondrial delivery system Download PDF

Info

Publication number
US20140178993A1
US20140178993A1 US14/036,597 US201314036597A US2014178993A1 US 20140178993 A1 US20140178993 A1 US 20140178993A1 US 201314036597 A US201314036597 A US 201314036597A US 2014178993 A1 US2014178993 A1 US 2014178993A1
Authority
US
United States
Prior art keywords
mitochondria
cells
cell
peptide
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/036,597
Inventor
Jui-Chih Chang
Chin-San Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changhua Christian Hospital
Original Assignee
Changhua Christian Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changhua Christian Hospital filed Critical Changhua Christian Hospital
Priority to US14/036,597 priority Critical patent/US20140178993A1/en
Publication of US20140178993A1 publication Critical patent/US20140178993A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from normal cells to replace dysfunctional mitochondria in deficient cells.
  • Pep-1 cell penetrating peptide
  • mitochondrial defects are involved in many diseases with unknown reasons and no cure is currently available.
  • Majority of the DNA mutations found in organelles (mitochondria) in cytoplasm are inherited genetic diseases; yet, some are caused by gene mutations.
  • the defects are usually passed from mothers to their children because each egg has thousands of mitochondria, and upon fertilization, the mitochondria of sperms were left outside of the zygote; hence, the mitochondrial DNA in the zygote all came from the mother.
  • the incidence of mitochondrial defects and the distribution of these rare diseases caused by mitochondrial DNA are random since each cell contains thousands of mitochondria, and each mitochondria has 2-10 mitochondrial DNA; which mitochondrial DNA has defects is uncertain.
  • Taiwan around 50 mitochondrial defects—related diseases were reported up to date, and these diseases are categorized as rare diseases; furthermore, roughly 300-400 domestic families in Taiwan are found to have mitochondrial DNA defects with a defect rate around 1/10,000.
  • Mitochondrial defects are widely involved in numerous diseases and malignancies with ever-changing clinical symptoms. For the age of the onset of the diseases, from newborn babies to adults, some symptoms are persistent and apparent (e.g. developmental retardation and seizure, etc); On the other hand, some are non-specific symptoms such as migraine and short stature, etc., and only become apparent when in poor physical conditions. Different organs may have various degrees of lesions, for instance, headache, seizures, dementia, cortical blindness, partial paralysis, mental retardation, motor development retardation, and brain stem abnormalities, etc.
  • a number of symptoms or diseases of aging are related to mitochondrial defects, including atherosclerosis, stroke, Parkinson's disease, Alzheimer's disease, and cancers.
  • Mitochondria are the main energy source in eukaryotic cells; moreover, cell growth, cell differentiation, and even cell death are all regulated by mitochondria.
  • Literatures indicate that cell fusion of stem cells and mitochondria-malfunctioned cells permit the delivery of mitochondria between cells, and consequently facilitate the repairing process of the damaged cells and restore the normal energy metabolism pathway. Therefore, positive or passive transplantation of “cell mitochondrion” has become an effective cell therapy method. Nonetheless, application of the technology remains limited due to different transplantation efficiency and cell properties. For example, only one cell can be treated using microinjection, and as a result, the efficiency of treatment is poor or the delivered mitochondria in treated cells are not transferred by fusion with other cells. Hence, no effective method that can positively deliver mitochondria into cells is available at present.
  • mitochondria transplantation was brought up in foreign literatures in 1998, and recent studies have also indicated that using transgenic technology to transplant mitochondria into embryos can enhance embryo development.
  • mitochondria were separated from mouse liver cells and microinjected into the zygotes at 2PN stage collected from either young or old mice. In vitro culture of the above zygotes showed that in young mice, the percentage of the embryos developed to the blastocyst stage were significantly higher in the experimental group (37.65%) than in the control group (20.91%); however, the hatching rate was not affected (experimental group is 1.76% and control group is 1.82%).
  • mitochondrial transgenic technologies include microinjection, cell infusion, tRNA transgenic system, and peptide-mediated mitochondrial delivery system (PMD). Their respective principles, treating objects, interventional methods, and advantages/disadvantages are shown in Table 1. Among which, the peptide-mediated mitochondrial delivery system (PMD) can process a large number of cells at one time, and the number of delivered mitochondria can be regulated accordingly; moreover, the process is simple and time efficient, and no advanced techniques are required.
  • PMD peptide-mediated mitochondrial delivery system
  • RIC cell fusion RNA import complex
  • RIC Treating MERRF patient- Mouse oocytes Human A549 Human MERRF objects derived ⁇ °cells treated patient-derived mitochondria fusion with Ethidium LB64 cells and cell line (B2 clone) Bromide to mitochondrial and human B143 ⁇ ° inhibit fusion cell line cells treated with mitochondria KSS (FLP32.39) Ethidium Bromide to inhibit mitochondria Interventional Cell penetrating Microinjection Co-culture Liposome methods peptide (Pep-1) coating Disadvantages 1. Delivery 1. One cell at a 1. Translocation 1. Tedious efficiency is time. of the healthy procedures. below 100%. 2. Time mitochondria 2. Advanced 2. Average consuming. into the technology numbers of 3. Requires damaged cells required. mitochondria advanced cannot be 3.
  • Pep-1 belongs to the cell penetrating peptide families and has the sequence as shown in SEQ ID NO: 1.
  • Pep-1 consists of 3 domains: hydrophobic domain (KETWWETWWTEW), hydrophilic domain (contains numerous lysine (K), KKKRKV), and spacer (SQP).
  • the peptide contains both hydrophobic and hydrophilic ends, and is an amphipathic peptide. These types of peptides are usually used as drug and enzyme carriers, and they deliver their cargos by forming the particles using hydrophobic ends which cannot dissolve in water.
  • Drugs or enzymes are then incorporated in a self-assembling reaction during the embedding process where the positive charge carried by hydrophilic domain binds to the negative charge on the cell membrane. Meanwhile, the hydrophobic domain integrates into the cell phospholipid bilayer and transports proteins into the cell.
  • the advantage of this method is that prior chemical treatment of the target protein is not required, and the mechanism of cell entry is positive delivery, which is independent of endocytosis. Thus, the target protein will not be directly catalyzed in lysosomes, and increase cytoplasm conservation. Previous studies have also shown that Pep-1 has no cell toxicity, and its delivery will not affect ligands binding to their receptors on the cell surface.
  • Pep-1 peptide used in the present invention has been applied in delivery of drugs and particles; nonetheless, delivery of mitochondria using Pep-1 is a new technology developed by the present invention.
  • PMD peptide-mediated mitochondrial delivery system
  • the procedures are easy to follow and time efficient, one labeling process can treat numerous cells, the desired mitochondria quantity ( ⁇ g) can be controlled accordingly, no cell toxicity under appropriate transplantation conditions, and transplantation efficiency can reach up to 80%.
  • the mitochondria delivered using this system will move to the original mitochondrial sites in the cells, and will not be catalyzed in the lysosomes; hence, the therapeutic effects can last at least one week.
  • the present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria, and can be used to treat cell mitochondrial degeneration and related diseases.
  • Pep-1 cell penetrating peptide
  • the present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria.
  • Pep-1 cell penetrating peptide
  • the present invention discloses a method of introduction of mitochondria into host cells, and comprises of the following features: using cell penetrating peptide that has the SEQ ID NO: 1 to label and deliver functional mitochondria and obtain peptide-mitochondria complexes; co-culture the peptide-mitochondria complexes with host cells for a specific period of time to allow introduction of the mitochondria into the host cells.
  • a method using cell penetrating peptide that has the SEQ ID NO: 1 to label and deliver mitochondria separated from healthy human cells, and to replace the mitochondria in damaged cells was developed.
  • the cell penetrating peptide contains three domains including hydrophobic domain (KETWWETWWTEW), hydrophilic domain (contains significant amount of Lysine (K), KKKRKV), and Spacer (SQP).
  • the peptide contains both hydrophobic and hydrophilic ends, and is an amphipathic peptide.
  • the principle of delivery is using the hydrophobic ends to gather together which cannot dissolve in water to incorporate drugs or enzymes in a self-assembling reaction during the process of embedding.
  • the positive charge carried by the hydrophilic point will bind to the negative charge on the cell membrane and the hydrophobic end will integrate into the cell lipid bilayer simultaneously, and deliver the proteins into the cells.
  • functional mitochondria were collected after separation from human wild type B143 fusion cell line harboring normal mitochondria, and 105 ⁇ g of mitochondria (separated from 2 ⁇ 10 7 cells) after quantification and labeled with Mitotracker Red was subjected to labeling with Pep-1 (SEQ ID NO: 1) for 1 h, and the resulted Pep-1/mitochondria complexes were then delivered into the host cells (5 ⁇ 10 4 cells) for 2 days.
  • Said host cells are human MERRF patient-derived B2 cells, and human B143 ⁇ ° cells in which the mitochondria was inhibited by ethidium bromide, and the transplanted cells were then subjected to cellular mitochondria function assessment after one day of culture.
  • the advantages of the peptide-mediated mitochondrial delivery system include simple procedures and time efficiency.
  • One labeling process can treat a large number of cells, the number of mitochondria ( ⁇ g) for delivery can be regulated accordingly, there is no cell toxicity under adequate transplantation conditions, and transplantation rate is up to 80%.
  • the mitochondria delivered by this system will move to the original mitochondrial sites in the cell, and will not be catalyzed in lysosomes. Hence, the effects of these mitochondria delivered by this system can last for at least a week.
  • FIG. 1 The design of the peptide-mediated mitochondrial delivery system (PMD).
  • FIG. 2 The delivery efficiency of quantum dots into human adipose-derived adult stem cell (ADAS) by different methods.
  • A Expression of the delivered quantum dots in cells.
  • B Fluorescence intensity scattered by the particles.
  • FIG. 3 Comparison of (A) target protein expression on the cell surface (one day post delivery) and (B) cell growth, of quantum dots delivered by different methods in human adipose-derived adult stem cell (ADAS).
  • ADAS human adipose-derived adult stem cell
  • FIG. 4 Comparison of (A) bone gene expression and alkaline phosphatase activity, and (B) calcium deposition of quantum dots delivered by different methods in human adipose-derived adult stem cell (ADAS).
  • ADAS human adipose-derived adult stem cell
  • FIG. 5 Comparison of (A) cartilage gene expression, (B) (C) extracellular matrix proteoglycan expression, and (D) type II collagen expression of quantum dots delivered by different methods in human adipose-derived adult stem cell (ADAS).
  • ADAS adipose-derived adult stem cell
  • FIG. 6 Schematic diagram of in vitro assessment for Peptide-mediated mitochondrial delivery system (PMD).
  • FIG. 7 (A) Pep-1 efficiently delivers mitochondria into cells (red fluorescence). (B) 75.5% (MitoB2) and 83.0%)(Mito ⁇ ° of the cells express Pep-1 labeled mitochondria.
  • FIG. 8 (A) Expression of Pep-1 labeled mitochondria in cells. Delivered mitochondria (red fluorescence) moved to the original mitochondrial sites in the cell (green fluorescence). (B) 3D scanning results of MERRF fibroblast cells after delivery of mitochondria indicated that mitochondria can successfully enter the cells and relocate to the original mitochondrial sites in cells.
  • FIG. 9 Assessment of mitochondrial functions.
  • A Mitochondrial membrane potential assay.
  • B Cell viability after glucose-starvation. *Significant differences found in control groups; + Significant differences found in experimental groups; # Significant differences found in MERRF B2 cells of the experimental groups.
  • C Cell proliferation assay. *Significant differences found in control groups; + Significant differences found in experimental groups; # Significant differences found in MERRF B2 cells of the experimental groups.
  • D Adenosine triphosphate (ATP) synthesis. *Significant differences found in control groups; + Significant differences found in experimental groups; # Significant differences found in MERRF B2 cells of the experimental groups.
  • E Cellular lactate assay. *Significant differences found in control groups; + Significant differences found in experimental groups; # Significant differences found in MERRF B2 cells of the experimental groups.
  • FIG. 10 Assessment of mitochondrial function, therapeutic effects, delivered at different concentrations in human MERRF LCL cells and MERRF fibroblasts.
  • A Mitochondrial membrane potential assay.
  • B Reactive oxygen species (ROS) stress test. *Significant differences found in control groups; + Significant differences found in experimental groups Nor: normal cells, Abr: abnormal cells
  • the present invention discloses a method using cell penetrating peptide that has the SEQ ID NO: 1 to label and deliver mitochondria separated from healthy human cells, and to replace the mitochondria in damaged cells.
  • Said peptide-mediated delivery system is shown in FIG. 1 .
  • the cell penetrating peptide contains three domains including hydrophobic domain (KETWWETWWTEW), hydrophilic domain (contains significant amount of Lysine (K), KKKRKV), and Spacer (SQP).
  • the peptide contains both hydrophobic and hydrophilic domains, and is an amphipathic peptide.
  • the principle of delivery is using particles that are hydrophobic, which cannot be dissolved in water.
  • the present invention also compares the methods using PolyFect reagents (TQ) which enhances the entry by endocytosis pathway and cell penetrating peptide (Pep-1), and demonstrates that delivery using Pep-1 can successfully deliver nanoparticle quantum dots (LQ).
  • TQ PolyFect reagents
  • Pep-1 has higher efficiency than PolyFect reagents (as shown in FIG. 2 ).
  • Pep-1 will not inhibit the expression of target proteins on the cell surface ( FIG. 3A ) and cell growth ( FIG. 3B ) in human adipose-derived adult stem cell (ADAS).
  • ADAS human adipose-derived adult stem cell
  • this type of delivery will not inhibit bone ( FIGS. 4A and 4B ) and cartilage differentiation ( FIGS. 5A , 5 B, and 5 C) of stem cells.
  • delivery using PolyFect reagents (TQ) will inhibit cell differentiation and disable micromass culture, which subsequently
  • Peptide Pep-1 can efficiently deliver mitochondria into cells (delivered healthy mitochondria labeled with red fluorescence) ( FIG. 7A ).
  • the delivery efficiency in human MERRF patient-derived B2 clones and human B143 ⁇ ° cells in which the mitochondria was inhibited by ethidium bromide are 75.5% (MitoB2) and 83.0% (Mito ⁇ °), respectively ( FIG. 7B ).
  • the mitochondria delivered using the present PMD system will move to the original sites of mitochondria in the cells ( FIG. 8A ).
  • Using MERRF fibroblast cells that overexpress mitochondria further shows that the transplanted mitochondria can successfully enter the cells and move to the original mitochondria sites in the cells ( FIG. 8B ).
  • PMD Peptide-mediated mitochondrial delivery system
  • the system is suitable for use in various types of cells that have functional mitochondria defects found in myoclonic epilepsy with ragged-red fibers (MERRF) syndrome which includes MERRF lymphocytes (MERRF LCL), and MERRF fibroblasts.
  • MERRF myoclonic epilepsy with ragged-red fibers
  • the peptide-mediated mitochondrial delivery system was shown to restore the function of damaged mitochondria of MERRF (Myoclonic Epilepsy with Ragged Red Fibers) patients-derived lymphocytes (MERRF LCL), and fibroblasts (MERRF fibroblasts).
  • MERRF LCL compared with the mitochondria concentrations prior to transportation: 0.05 ⁇ , 0.1 ⁇ , 0.2 ⁇
  • MERRF fibroblasts compared with the mitochondria concentrations prior to transportation: 0.05 ⁇ , 0.1 ⁇ , 0.2 ⁇
  • mitochondria malfunction caused by gene mutations in mitochondria are notably reduced, including increased mitochondrial potential (increased fluorescence expression of JC1 aggregates)( FIG. 10A ), and reduced production of intracellular reactive oxygen species (ROS) ( FIG. 10B ).
  • ROS intracellular reactive oxygen species
  • the peptide-mediated mitochondrial delivery system (PMD) described in the present invention has the following advantages when compared with other well-known systems used for delivering mitochondria:
  • the delivered particles will not activate cell metabolism pathways, and can be catalyzed.
  • the peptide-mediated mitochondrial delivery system is a feasible technology and has been proved in the examples mentioned above.
  • Pep-1 has been used in delivery of drugs and particles
  • delivery of mitochondria using Pep-1 is a new technology developed by the present invention.
  • the present system also includes an advanced mitochondria separation method.
  • the procedures of the PMD system are easy to follow and very efficient.
  • One labeling process can treat numerous cells, the desired mitochondria quantity ( ⁇ g) can be controlled accordingly, there is no cell toxicity under appropriate transplantation conditions, and most importantly, transplantation efficiency is up to 80%.
  • the mitochondria delivered using this system will not only move to the original mitochondrial sites in the cell, but will not be catalyzed in the lysosomes; hence, the therapeutic effects can last at least one week.
  • the peptides used in the invention are not toxic; however, preliminary evaluation to determine the adequate number of mitochondria for delivery for optimal results is required.
  • the effective number of delivered mitochondria in different types of cells may vary accordingly. For example, as shown in the present invention, after calculation of the ratios of the peptides, 105 ⁇ g of mitochondria is effective in treating 50,000 mutant mitochondria in B2 cybrids cells derived from MERRF patients. Excess delivery of mitochondria may result in cell stress and induce cell growth arrest.
  • the present invention meet the requirements of Article 33 (2) PCT and 33(3) PCT, and therefore, is considered novel and inventive.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria. At present, microinjection of mitochondria into cells can only process one cell at a time, and therefore, this technique is limited to embryo related research and relevant applications. The advantages of the said peptide-mediated mitochondrial delivery system (PMD) include less steps with more efficiency, where a number of cells can be treated following one labeling process; the delivery process can be easily controlled, there is no cell toxicity after delivery under appropriate conditions, and delivery efficiency is over 80% depending on different cell types. Mitochondria delivered by the PMD system will move to the original mitochondrial location in the cells and will not be catalyzed in lysosomes; thus, the therapeutic effects can last at least one week.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application is a division of U.S. patent application Ser. No. 13/315,432 filed on Dec. 9, 2011, which is incorporated by reference herein in its entirety.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from normal cells to replace dysfunctional mitochondria in deficient cells.
  • 2. Description of the Prior Art
  • The necessity and demand for mitochondria transplantation is high because mitochondrial defects are involved in many diseases with unknown reasons and no cure is currently available. Majority of the DNA mutations found in organelles (mitochondria) in cytoplasm are inherited genetic diseases; yet, some are caused by gene mutations. The defects are usually passed from mothers to their children because each egg has thousands of mitochondria, and upon fertilization, the mitochondria of sperms were left outside of the zygote; hence, the mitochondrial DNA in the zygote all came from the mother. The incidence of mitochondrial defects and the distribution of these rare diseases caused by mitochondrial DNA, are random since each cell contains thousands of mitochondria, and each mitochondria has 2-10 mitochondrial DNA; which mitochondrial DNA has defects is uncertain. In Taiwan, around 50 mitochondrial defects—related diseases were reported up to date, and these diseases are categorized as rare diseases; furthermore, roughly 300-400 domestic families in Taiwan are found to have mitochondrial DNA defects with a defect rate around 1/10,000.
  • Mitochondrial defects are widely involved in numerous diseases and malignancies with ever-changing clinical symptoms. For the age of the onset of the diseases, from newborn babies to adults, some symptoms are persistent and apparent (e.g. developmental retardation and seizure, etc); On the other hand, some are non-specific symptoms such as migraine and short stature, etc., and only become apparent when in poor physical conditions. Different organs may have various degrees of lesions, for instance, headache, seizures, dementia, cortical blindness, partial paralysis, mental retardation, motor development retardation, and brain stem abnormalities, etc. found in the brain; different levels of muscular abnormalities; myocardial hypertrophy, atrioventricular conduction abnormalities found in the heart; eyelids dropping, outer eye muscle paralysis, optic nerve degeneration, and retinopathy found in eyes; kidney tubular function abnormalities; liver function abnormalities; vomiting, diarrhea, pseudo intestinal obstruction found in the GI tract; diabetes caused by defects in the pancreas, and bone marrow malfunction. Other symptoms include deafness, short stature, injury to the peripheral nervous system, and subcutaneous lipoma, etc. In addition, a number of symptoms or diseases of aging are related to mitochondrial defects, including atherosclerosis, stroke, Parkinson's disease, Alzheimer's disease, and cancers.
  • Up to date, there are no cures available for mitochondria-related diseases and the most common treatment is vitamins or pyruvate. Yet, several therapies have been developed along with the expanding medical knowledge of mitochondria-related diseases, and these treatments can assess individual conditions and improve the symptoms. Theoretically, maternally inherited mitochondrial genetic defects may be prevented by transplantation using microinjection of single embryo mitochondria; however, for mutations in mitochondria caused by external factors such as oxidation stress or poor quality of the mitochondria, the present invention can provide a method that can significantly improve the efficiency of transplantation of mitochondria into a large number of cells at one time.
  • Mitochondria are the main energy source in eukaryotic cells; moreover, cell growth, cell differentiation, and even cell death are all regulated by mitochondria. Literatures indicate that cell fusion of stem cells and mitochondria-malfunctioned cells permit the delivery of mitochondria between cells, and consequently facilitate the repairing process of the damaged cells and restore the normal energy metabolism pathway. Therefore, positive or passive transplantation of “cell mitochondrion” has become an effective cell therapy method. Nonetheless, application of the technology remains limited due to different transplantation efficiency and cell properties. For example, only one cell can be treated using microinjection, and as a result, the efficiency of treatment is poor or the delivered mitochondria in treated cells are not transferred by fusion with other cells. Hence, no effective method that can positively deliver mitochondria into cells is available at present.
  • The idea of mitochondria transplantation was brought up in foreign literatures in 1998, and recent studies have also indicated that using transgenic technology to transplant mitochondria into embryos can enhance embryo development. To evaluate the effects of mitochondria transplantation on embryo development, mitochondria were separated from mouse liver cells and microinjected into the zygotes at 2PN stage collected from either young or old mice. In vitro culture of the above zygotes showed that in young mice, the percentage of the embryos developed to the blastocyst stage were significantly higher in the experimental group (37.65%) than in the control group (20.91%); however, the hatching rate was not affected (experimental group is 1.76% and control group is 1.82%). Even for the zygotes collected from older mice (about 20 weeks old), development of these embryos in the control group was also notably improved (experimental group vs. control group is 54.35% vs. 18.92% and 43.48% vs. 8.11% for embryos at morula stage and blastocyst stage, respectively. Due to ethical issues and potential risks including mitochondria heterogeneity and effects on cell activity, etc. relevant studies focused on mitochondrial transplantation in humans are not currently available. Additionally, whether the mode of transplantation is suitable for use in other cell types or other interventions are applicable requires further investigation.
  • Currently, mitochondrial transgenic technologies include microinjection, cell infusion, tRNA transgenic system, and peptide-mediated mitochondrial delivery system (PMD). Their respective principles, treating objects, interventional methods, and advantages/disadvantages are shown in Table 1. Among which, the peptide-mediated mitochondrial delivery system (PMD) can process a large number of cells at one time, and the number of delivered mitochondria can be regulated accordingly; moreover, the process is simple and time efficient, and no advanced techniques are required.
  • TABLE 1
    Comparison of mitochondrial transgenic technologies.
    Peptide-mediated
    mitochondrial tRNA transgenic
    Method delivery system Microinjection Cell fusion system
    Principle Delivers Delivers Passive delivery Delivers
    mitochondria mitochondria via mitochondrial mitochondria
    obtained and separated from interaction separated from
    separated from healthy cells induced by stem Leishmania
    healthy cells. cell fusion RNA import
    complex (RIC)
    Treating MERRF patient- Mouse oocytes Human A549 Human MERRF
    objects derived ρ°cells treated patient-derived
    mitochondria fusion with Ethidium LB64 cells and
    cell line (B2 clone) Bromide to mitochondrial
    and human B143 ρ° inhibit fusion cell line
    cells treated with mitochondria KSS (FLP32.39)
    Ethidium Bromide
    to inhibit
    mitochondria
    Interventional Cell penetrating Microinjection Co-culture Liposome
    methods peptide (Pep-1) coating
    Disadvantages
    1. Delivery 1. One cell at a 1. Translocation 1. Tedious
    efficiency is time. of the healthy procedures.
    below 100%. 2. Time mitochondria 2. Advanced
    2. Average consuming. into the technology
    numbers of 3. Requires damaged cells required.
    mitochondria advanced cannot be 3. High cost and
    delivered into the technology. controlled. pre-treatment
    cells cannot be 2. Not suitable is time-
    controlled for all cell consuming
    accurately. types, because 4. tRNA cannot
    cell fusion be stored ∘
    may not occur
    in certain cells
    even after co-
    culture.
    Advantages 1. Large number of Single cell 1. No active Direct regulation
    cells can be transgenic rate interventions. of tRNA
    treated at one is up to 100%. 2. The simplest proteins, and can
    time. and least completely
    2. The process of expensive repair the
    mitochondrial method. defects caused
    delivery can be by mutations in
    regulated mitochondrial
    accordingly. DNA.
    3. No advanced
    technology
    required.
  • Cell penetrating peptide (Pep-1) belongs to the cell penetrating peptide families and has the sequence as shown in SEQ ID NO: 1. Pep-1 consists of 3 domains: hydrophobic domain (KETWWETWWTEW), hydrophilic domain (contains numerous lysine (K), KKKRKV), and spacer (SQP). The peptide contains both hydrophobic and hydrophilic ends, and is an amphipathic peptide. These types of peptides are usually used as drug and enzyme carriers, and they deliver their cargos by forming the particles using hydrophobic ends which cannot dissolve in water. Drugs or enzymes are then incorporated in a self-assembling reaction during the embedding process where the positive charge carried by hydrophilic domain binds to the negative charge on the cell membrane. Meanwhile, the hydrophobic domain integrates into the cell phospholipid bilayer and transports proteins into the cell. The advantage of this method is that prior chemical treatment of the target protein is not required, and the mechanism of cell entry is positive delivery, which is independent of endocytosis. Thus, the target protein will not be directly catalyzed in lysosomes, and increase cytoplasm conservation. Previous studies have also shown that Pep-1 has no cell toxicity, and its delivery will not affect ligands binding to their receptors on the cell surface.
  • Pep-1 peptide used in the present invention has been applied in delivery of drugs and particles; nonetheless, delivery of mitochondria using Pep-1 is a new technology developed by the present invention. In addition, by combination of the advanced mitochondria separation method, we further developed the peptide-mediated mitochondrial delivery system (PMD) which has the following advantages: the procedures are easy to follow and time efficient, one labeling process can treat numerous cells, the desired mitochondria quantity (μg) can be controlled accordingly, no cell toxicity under appropriate transplantation conditions, and transplantation efficiency can reach up to 80%. The mitochondria delivered using this system will move to the original mitochondrial sites in the cells, and will not be catalyzed in the lysosomes; hence, the therapeutic effects can last at least one week.
  • The present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria, and can be used to treat cell mitochondrial degeneration and related diseases.
  • In summary, after years of painstaking research, the inventor(s) of the present invention successfully developed the novel peptide-mediated mitochondrial delivery system (PMD) and demonstrated various applications of the newly developed system.
    • SUMMARY OF THE INVENTION
  • The present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria.
  • In one aspect, the present invention discloses a method of introduction of mitochondria into host cells, and comprises of the following features: using cell penetrating peptide that has the SEQ ID NO: 1 to label and deliver functional mitochondria and obtain peptide-mitochondria complexes; co-culture the peptide-mitochondria complexes with host cells for a specific period of time to allow introduction of the mitochondria into the host cells.
  • In a further embodiment of the invention, a method using cell penetrating peptide that has the SEQ ID NO: 1 to label and deliver mitochondria separated from healthy human cells, and to replace the mitochondria in damaged cells was developed. The cell penetrating peptide contains three domains including hydrophobic domain (KETWWETWWTEW), hydrophilic domain (contains significant amount of Lysine (K), KKKRKV), and Spacer (SQP). The peptide contains both hydrophobic and hydrophilic ends, and is an amphipathic peptide. The principle of delivery is using the hydrophobic ends to gather together which cannot dissolve in water to incorporate drugs or enzymes in a self-assembling reaction during the process of embedding. The positive charge carried by the hydrophilic point will bind to the negative charge on the cell membrane and the hydrophobic end will integrate into the cell lipid bilayer simultaneously, and deliver the proteins into the cells.
  • In another embodiment, functional mitochondria were collected after separation from human wild type B143 fusion cell line harboring normal mitochondria, and 105 μg of mitochondria (separated from 2×107 cells) after quantification and labeled with Mitotracker Red was subjected to labeling with Pep-1 (SEQ ID NO: 1) for 1 h, and the resulted Pep-1/mitochondria complexes were then delivered into the host cells (5×104 cells) for 2 days. Said host cells are human MERRF patient-derived B2 cells, and human B143 ρ° cells in which the mitochondria was inhibited by ethidium bromide, and the transplanted cells were then subjected to cellular mitochondria function assessment after one day of culture.
  • The advantages of the peptide-mediated mitochondrial delivery system (PMD) include simple procedures and time efficiency. One labeling process can treat a large number of cells, the number of mitochondria (μg) for delivery can be regulated accordingly, there is no cell toxicity under adequate transplantation conditions, and transplantation rate is up to 80%. The mitochondria delivered by this system will move to the original mitochondrial sites in the cell, and will not be catalyzed in lysosomes. Hence, the effects of these mitochondria delivered by this system can last for at least a week. According to present study, by using human MERRF patient-derived B2 cells and human B143 ρ° cells in which the mitochondria was inhibited by ethidium bromide as models, we provide evidence indicating that this PMD system can be used for treating mitochondrial degeneration and relevant diseases.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 The design of the peptide-mediated mitochondrial delivery system (PMD).
  • FIG. 2 The delivery efficiency of quantum dots into human adipose-derived adult stem cell (ADAS) by different methods. (A) Expression of the delivered quantum dots in cells. (B) Fluorescence intensity scattered by the particles.
      • C: control group, LQ: Pep-1 group, TQ: PolyFect group.
  • FIG. 3 Comparison of (A) target protein expression on the cell surface (one day post delivery) and (B) cell growth, of quantum dots delivered by different methods in human adipose-derived adult stem cell (ADAS).
      • C: control group, LQ: Pep-1 group, TQ: PolyFect group.
      • (# means significant difference in group C, and significant difference in group LQ).
  • FIG. 4 Comparison of (A) bone gene expression and alkaline phosphatase activity, and (B) calcium deposition of quantum dots delivered by different methods in human adipose-derived adult stem cell (ADAS).
      • C: control group, LQ: Pep-1 group, TQ: PolyFect group.
  • FIG. 5 Comparison of (A) cartilage gene expression, (B) (C) extracellular matrix proteoglycan expression, and (D) type II collagen expression of quantum dots delivered by different methods in human adipose-derived adult stem cell (ADAS).
      • C: control group, LQ: Pep-1 group, TQ: PolyFect group.
  • FIG. 6 Schematic diagram of in vitro assessment for Peptide-mediated mitochondrial delivery system (PMD).
  • FIG. 7 (A) Pep-1 efficiently delivers mitochondria into cells (red fluorescence). (B) 75.5% (MitoB2) and 83.0%)(Mitoρ° of the cells express Pep-1 labeled mitochondria.
  • FIG. 8 (A) Expression of Pep-1 labeled mitochondria in cells. Delivered mitochondria (red fluorescence) moved to the original mitochondrial sites in the cell (green fluorescence). (B) 3D scanning results of MERRF fibroblast cells after delivery of mitochondria indicated that mitochondria can successfully enter the cells and relocate to the original mitochondrial sites in cells.
  • FIG. 9 Assessment of mitochondrial functions. (A) Mitochondrial membrane potential assay. (B) Cell viability after glucose-starvation. *Significant differences found in control groups; + Significant differences found in experimental groups; # Significant differences found in MERRF B2 cells of the experimental groups. (C) Cell proliferation assay. *Significant differences found in control groups; + Significant differences found in experimental groups; # Significant differences found in MERRF B2 cells of the experimental groups. (D) Adenosine triphosphate (ATP) synthesis. *Significant differences found in control groups; + Significant differences found in experimental groups; # Significant differences found in MERRF B2 cells of the experimental groups. (E) Cellular lactate assay. *Significant differences found in control groups; + Significant differences found in experimental groups; # Significant differences found in MERRF B2 cells of the experimental groups.
  • FIG. 10 Assessment of mitochondrial function, therapeutic effects, delivered at different concentrations in human MERRF LCL cells and MERRF fibroblasts. (A) Mitochondrial membrane potential assay. (B) Reactive oxygen species (ROS) stress test. *Significant differences found in control groups; + Significant differences found in experimental groups Nor: normal cells, Abr: abnormal cells
    •  DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
  • The invention will be better understood when read in conjunction with the following detailed examples; however, the present invention is not limited to the preferred embodiments shown in the drawings.
    • Example 1 Detailed Description of the Peptide-Mediated Delivery System 1. Technical Process:
  • The present invention discloses a method using cell penetrating peptide that has the SEQ ID NO: 1 to label and deliver mitochondria separated from healthy human cells, and to replace the mitochondria in damaged cells. Said peptide-mediated delivery system is shown in FIG. 1. The cell penetrating peptide contains three domains including hydrophobic domain (KETWWETWWTEW), hydrophilic domain (contains significant amount of Lysine (K), KKKRKV), and Spacer (SQP). The peptide contains both hydrophobic and hydrophilic domains, and is an amphipathic peptide. The principle of delivery is using particles that are hydrophobic, which cannot be dissolved in water. These gather together to incorporate drugs or enzymes through a self-assembling reaction produced in the process of embedding. The positive charge carried by the hydrophilic group will bind to the negative charge on the cell membrane and the hydrophobic group will integrate into the cell lipid bilayer simultaneously, and deliver the protein into the cell. The advantages of this delivery method are that the prior chemical cross reaction of the target protein is not required, and the mechanism of delivery is by active transport which is independent of passive endocytosis; thus, the delivered proteins will not be catalyzed directly in lysosomes, and will consequently increase conservation of the cytoplasm. The literature indicates that Pep-1 has no cell toxicity, and its method of transportation will not affect ligands binding to the cell surface receptors on the host cells.
    • 2. Experimental Results of Delivering Nanoparticles (Quantum Dots) Similar to the Size of a Mitochondrion Using the Peptide.
  • The present invention also compares the methods using PolyFect reagents (TQ) which enhances the entry by endocytosis pathway and cell penetrating peptide (Pep-1), and demonstrates that delivery using Pep-1 can successfully deliver nanoparticle quantum dots (LQ). According to the fluorescence intensity, Pep-1 has higher efficiency than PolyFect reagents (as shown in FIG. 2). Meanwhile, Pep-1 will not inhibit the expression of target proteins on the cell surface (FIG. 3A) and cell growth (FIG. 3B) in human adipose-derived adult stem cell (ADAS). Furthermore, this type of delivery will not inhibit bone (FIGS. 4A and 4B) and cartilage differentiation (FIGS. 5A, 5B, and 5C) of stem cells. In contrast, delivery using PolyFect reagents (TQ) will inhibit cell differentiation and disable micromass culture, which subsequently results in immature cartilage cells.
    • Example 2 Assessment of the Therapeutic Effects 1. In Vitro Assessment of Peptide-Mediated Mitochondrial Delivery System (PMD):
  • Functional and normal mitochondria were separated from human B143 cell line harboring normal mitochondria, and 105 μg mitochondria (separated from 1×107 cells) was quantified and labeled with Mitotracker Red first, and then with Pep-1 (SEQ ID NO: 1) for 1 hour. The resulted Pep-1/mitochondria complexes were subsequently delivered into the host cells for 2 days (5×104 cells). Said host cells are human MERRF patient-derived B2 cells and human B143 ρ° cells in which the mitochondria was inhibited by ethidium bromide, and the transplanted cells were subjected to cellular mitochondrial function assessment after one day of culture (as shown in FIG. 6).
    • 2. Confirmation and Assessment of the Therapeutic Effects
  • (1) Mitochondrial Delivery Efficiency and Regular Follow Up
  • Peptide Pep-1 can efficiently deliver mitochondria into cells (delivered healthy mitochondria labeled with red fluorescence) (FIG. 7A). The delivery efficiency in human MERRF patient-derived B2 clones and human B143ρ° cells in which the mitochondria was inhibited by ethidium bromide are 75.5% (MitoB2) and 83.0% (Mitoρ°), respectively (FIG. 7B).
  • (2) In Vitro Expression of Peptide-1 Labeled Mitochondria.
  • The mitochondria delivered using the present PMD system will move to the original sites of mitochondria in the cells (FIG. 8A). Using MERRF fibroblast cells that overexpress mitochondria further shows that the transplanted mitochondria can successfully enter the cells and move to the original mitochondria sites in the cells (FIG. 8B).
  • (3) Evaluation of the Repair Function of Peptide-1 Targeted Mitochondria.
  • Peptide-mediated mitochondrial delivery system (PMD) has no cell toxicity, and can be used to treat cell mitochondrial malfunction caused by mutations in mitochondrial DNA, including recovering mitochondrial membrane potential (reduced JC1 monomers fluorescence expression) (FIG. 9A), prolonging cell survival in low-sugar culture condition (FIG. 9C), recovering production of cell energy (FIG. 9D), and reducing lactate produced in anaerobic metabolism process (FIG. 9E). The therapeutic effects of PMD last at least one week.
  • (4) According to the results, the system is suitable for use in various types of cells that have functional mitochondria defects found in myoclonic epilepsy with ragged-red fibers (MERRF) syndrome which includes MERRF lymphocytes (MERRF LCL), and MERRF fibroblasts.
  • The peptide-mediated mitochondrial delivery system (PMD) was shown to restore the function of damaged mitochondria of MERRF (Myoclonic Epilepsy with Ragged Red Fibers) patients-derived lymphocytes (MERRF LCL), and fibroblasts (MERRF fibroblasts). At appropriate mitochondria concentration, MERRF LCL (compared with the mitochondria concentrations prior to transportation: 0.05×, 0.1×, 0.2×) and MERRF fibroblasts (compared with the mitochondria concentrations prior to transportation: 0.05×, 0.1×, 0.2×), mitochondria malfunction caused by gene mutations in mitochondria are notably reduced, including increased mitochondrial potential (increased fluorescence expression of JC1 aggregates)(FIG. 10A), and reduced production of intracellular reactive oxygen species (ROS) (FIG. 10B).
  • The peptide-mediated mitochondrial delivery system (PMD) described in the present invention has the following advantages when compared with other well-known systems used for delivering mitochondria:
  • 1. No cell toxicity effects on the host cells.
  • 2. Efficient delivery of nanoparticles into stem cells and no effects on stem cell differentiation.
  • 3. The delivered particles will not activate cell metabolism pathways, and can be catalyzed.
  • Taken together, the peptide-mediated mitochondrial delivery system is a feasible technology and has been proved in the examples mentioned above. Though Pep-1 has been used in delivery of drugs and particles, delivery of mitochondria using Pep-1 is a new technology developed by the present invention. In addition, the present system also includes an advanced mitochondria separation method. The procedures of the PMD system are easy to follow and very efficient. One labeling process can treat numerous cells, the desired mitochondria quantity (μg) can be controlled accordingly, there is no cell toxicity under appropriate transplantation conditions, and most importantly, transplantation efficiency is up to 80%. The mitochondria delivered using this system will not only move to the original mitochondrial sites in the cell, but will not be catalyzed in the lysosomes; hence, the therapeutic effects can last at least one week. According to the results, using MERRF B2 cell line derived from patients with MERRF syndrome, and human B143 ρ° cell line in which mitochondria were inhibited by ethidium bromide as models, we demonstrated that the present system can be used for treating cell mitochondrial degeneration and related diseases. Furthermore, this study further confirmed the feasibility of the present system in that with adequate mitochondria transplantation numbers, therapeutic effects are outstanding by using different cells derived from MERRF patients, including MERRF LCL and MERRF fibroblasts.
  • The peptides used in the invention are not toxic; however, preliminary evaluation to determine the adequate number of mitochondria for delivery for optimal results is required. The effective number of delivered mitochondria in different types of cells may vary accordingly. For example, as shown in the present invention, after calculation of the ratios of the peptides, 105 μg of mitochondria is effective in treating 50,000 mutant mitochondria in B2 cybrids cells derived from MERRF patients. Excess delivery of mitochondria may result in cell stress and induce cell growth arrest.
  • The foregoing descriptions are detailed examples to better elucidate the present invention; however, the applications of the present invention is not limited to the description provided here, and all related modifications/applications should be included in the present invention.
  • In summary, the present invention meet the requirements of Article 33 (2) PCT and 33(3) PCT, and therefore, is considered novel and inventive.

Claims (6)

What is claimed is:
1. A composition for introducing a mitochondria into host cells comprising a peptide that has the SEQ ID NO: 1, a normal and functional mitochondria, and a pharmaceutical acceptable excipient.
2. The composition according to claim 1, wherein the normal mitochondria in the composition is obtained from normal cells after separation.
3. The composition according to claim 2, wherein the normal and functional mitochondria in the composition is obtained from normal human cells after separation.
4. The composition according to claim 1, wherein the peptide is an amphipathic peptide and contains both hydrophilic and hydrophobic groups.
5. The composition according to claim 4, wherein the peptide contains hydrophobic domain, hydrophilic domain, and spacers.
6. The composition according to claim 1, wherein the excipients are diluents, fillers, binders, disintegrating agents, or lubricants.
US14/036,597 2011-12-09 2013-09-25 Method and applications of peptide-mediated mitochondrial delivery system Abandoned US20140178993A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/036,597 US20140178993A1 (en) 2011-12-09 2013-09-25 Method and applications of peptide-mediated mitochondrial delivery system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/315,432 US8648034B2 (en) 2011-12-09 2011-12-09 Method and applications of peptide-mediated mitochondrial delivery system
US14/036,597 US20140178993A1 (en) 2011-12-09 2013-09-25 Method and applications of peptide-mediated mitochondrial delivery system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/315,432 Division US8648034B2 (en) 2011-12-09 2011-12-09 Method and applications of peptide-mediated mitochondrial delivery system

Publications (1)

Publication Number Publication Date
US20140178993A1 true US20140178993A1 (en) 2014-06-26

Family

ID=48572328

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/315,432 Active 2031-12-18 US8648034B2 (en) 2011-12-09 2011-12-09 Method and applications of peptide-mediated mitochondrial delivery system
US14/036,597 Abandoned US20140178993A1 (en) 2011-12-09 2013-09-25 Method and applications of peptide-mediated mitochondrial delivery system

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/315,432 Active 2031-12-18 US8648034B2 (en) 2011-12-09 2011-12-09 Method and applications of peptide-mediated mitochondrial delivery system

Country Status (1)

Country Link
US (2) US8648034B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017124037A1 (en) * 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
US11491480B2 (en) 2014-06-13 2022-11-08 Children's Medical Center Corporation Products and methods to isolate mitochondria
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035101A1 (en) 2011-09-11 2013-03-14 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
CN104630149B (en) * 2013-11-08 2018-08-21 中国科学院广州生物医药与健康研究院 Xenogenic mitochondrial imported into the method in mammalian cell
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
EP3261649A4 (en) 2015-02-26 2018-08-15 Minovia Therapeutics Ltd. Mammalian cells enriched with functional mitochondria
EP3261677B1 (en) * 2015-02-27 2019-04-10 University of Connecticut Targeted transplantation of mitochondria to hepatocytes
CN106399372A (en) * 2016-10-18 2017-02-15 广西壮族自治区水牛研究所(中国农业科学院水牛研究所) Method for transducing buffalo embryo by virtue of PEP-1 peptide mediated green fluorescent protein
CN106480091B (en) * 2016-10-18 2019-08-30 广西壮族自治区水牛研究所(中国农业科学院水牛研究所) A method for PEP-1 peptide tandem to mediate green fluorescent protein transduction of buffalo embryos
WO2019028469A1 (en) * 2017-08-04 2019-02-07 The Methodist Hospital Polymer-functionalized mitochondrial compositions and methods of use in cellular transplantation and for altering metabolic phenotype
EP3823640A4 (en) 2018-07-22 2022-05-18 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of muscle diseases
EP3823646A4 (en) 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF BRAIN DISEASES
EP3823645B1 (en) 2018-07-22 2024-07-03 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
EP3823641A4 (en) 2018-07-22 2022-05-18 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of ocular diseases
WO2020163856A1 (en) * 2019-02-10 2020-08-13 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Modified mitochondrion and methods of use thereof

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11491480B2 (en) 2014-06-13 2022-11-08 Children's Medical Center Corporation Products and methods to isolate mitochondria
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
US11903975B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from blood products
WO2017124037A1 (en) * 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
JP2019507729A (en) * 2016-01-15 2019-03-22 ザ チルドレンズ メディカル センター コーポレーション Therapeutic use of mitochondria and combined mitochondrial agents
US10370458B2 (en) 2016-01-15 2019-08-06 Children's Medical Center Corporation and Beth Israel Therapeutic use of mitochondria and combined mitochondrial agent
EP3735976A3 (en) * 2016-01-15 2021-01-27 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
AU2017208013B2 (en) * 2016-01-15 2022-12-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic use of mitochondria and combined mitochondrial agents
JP7185527B2 (en) 2016-01-15 2022-12-07 ザ チルドレンズ メディカル センター コーポレーション Therapeutic use of mitochondria and combined mitochondrial agents
JP2024161552A (en) * 2016-01-15 2024-11-19 ザ チルドレンズ メディカル センター コーポレーション Therapeutic Uses of Mitochondria and Combined Mitochondrial Agents
US12168700B2 (en) 2016-01-15 2024-12-17 Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
AU2023201193B2 (en) * 2016-01-15 2025-01-23 Beth Israel Deaconess Medical Center, Inc. Therapeutic use of mitochondria and combined mitochondrial agents

Also Published As

Publication number Publication date
US8648034B2 (en) 2014-02-11
US20130149778A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
US8648034B2 (en) Method and applications of peptide-mediated mitochondrial delivery system
Paradies et al. Role of cardiolipin in mitochondrial function and dynamics in health and disease: molecular and pharmacological aspects
Wakayama et al. Establishment of male and female nuclear transfer embryonic stem cell lines from different mouse strains and tissues
Zhang et al. Retinal ganglion cell transplantation: approaches for overcoming challenges to functional integration
US8999714B2 (en) Mitochondrial enhancement of cells
Yasuda et al. Multiple forms of activity-dependent competition refine hippocampal circuits in vivo
Mayeur et al. Potential of olfactory ensheathing cells from different sources for spinal cord repair
Li et al. Retinal organoids: cultivation, differentiation, and transplantation
Kouwenhoven et al. VGluT2 expression in dopamine neurons contributes to postlesional striatal reinnervation
Boal et al. Astrocyte networks as therapeutic targets in glaucomatous neurodegeneration
CN1146712A (en) Myoblast therapy for mammalian diseases
Zhang et al. Stem cell-based regeneration and restoration for retinal ganglion cell: recent advancements and current challenges
Echigoya et al. A dystrophin exon-52 deleted miniature pig model of Duchenne muscular dystrophy and evaluation of exon skipping
Aghaizu et al. Repeated nuclear translocations underlie photoreceptor positioning and lamination of the outer nuclear layer in the mammalian retina
Fu et al. Extracellular vesicles function as bioactive molecular transmitters in the mammalian oviduct: an inspiration for optimizing in vitro culture systems and improving delivery of exogenous nucleic acids during preimplantation embryonic development
Ashworth et al. Inherited retinal diseases and retinal organoids as preclinical cell models for inherited retinal disease research
Arthur et al. Bioengineering human pluripotent stem cell-derived retinal organoids and optic vesicle-containing brain organoids for ocular diseases
Neikirk et al. Considerations for developing mitochondrial transplantation techniques for individualized medicine
Guo et al. Inducible Rbpms-CreERT2 Mouse Line for Studying Gene Function in Retinal Ganglion Cell Physiology and Disease
Tscherner et al. Oocyte-specific deletion of Slc6a9 encoding the GLYT1 glycine transporter eliminates glycine transport in mouse preimplantation embryos and their ability to counter hypertonic stress
Xie et al. Secondary follicles enable efficient germline mtDNA base editing at hard-to-edit site
Lei et al. Integration and differentiation of transplanted human iPSC-derived retinal ganglion cell precursors in murine retinas
Yuan et al. Brain-derived neurotrophic factor-modified umbilical cord mesenchymal stem cell transplantation improves neurological deficits in rats with traumatic brain injury
Coward et al. Expression of a fluorescent recombinant form of sperm protein phospholipase C zeta in mouse epididymal sperm by in vivo gene transfer into the testis
Zeng et al. Genetically engineered pigs as efficient salivary gland bioreactors for production of therapeutically valuable human nerve growth factor

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION